Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Wedbush Reiterates Outperform on Elevation Oncology, Maintains $4 Price Target

Wedbush Reiterates Outperform on Elevation Oncology, Maintains $4 Price Target

Wedbush analyst Robert Driscoll reiterates Elevation Oncology (NASDAQ:ELEV) with a Outperform and maintains $4 price target.

March 10, 2023

1 minute read

Wedbush analyst Robert Driscoll reiterates Elevation Oncology (NASDAQ:ELEV) with a Outperform and maintains $4 price target.

Root Stock Rips Higher Following Q1 Earnings: The Details

April 30, 5:25 PM

Root says it "nearly quadrupled" total new writings and grew policies-in-force 101% on a year-over-year basis.

January 23, 10:31 AM

Morgan Stanley analyst Ronald Kamdem maintains Prologis (NYSE:PLD) with a Overweight and raises the price target from $121 to $128.

July 20, 8:00 AM

Credit Suisse analyst Ariel Rosa maintains JB Hunt Transport Servs (NASDAQ:JBHT) with a Neutral and raises the price target from $178 to $185.

April 27, 12:34 PM

Hertz Global Holdings Inc (NASDAQ:HTZ) reported Q1 2023 revenue growth of 13% Y/Y to $2.05 billion, beating the consensus of…